FRANKLIN LAKES, N.J., February 20, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD Synapsys™ microbiology informatics solution, the company’s integrated diagnostics informatics platform, has been certified by the Underwriters Laboratory Cybersecurity Assurance Program (UL CAP). This independent program uses standardized, testable criteria for assessing software vulnerabilities and weaknesses.
The BD Synapsys informatics solution is among the first life-science diagnostics informatics platforms to meet all UL CAP cybersecurity standards.
“Cybersecurity is top of mind for our customers,” said Dave Hickey, president, BD Life Sciences - Integrated Diagnostic Solutions (IDS). “Securing connected solutions is essential to patient safety and privacy. By being among the first in the diagnostics space to receive UL CAP certification for an informatics platform, BD is demonstrating its ongoing commitment to taking a proactive approach to cybersecurity.”
BD Synapsys solution is an advanced browser-based informatics solution to help laboratories improve their performance by providing connectivity for BD diagnostics instruments, rules-based workflow management tools to enable efficient lab workflow, tools to streamline communication with laboratory stakeholders, and on-demand insights to help laboratories improve performance.
As a key component in the diagnostic process, a cybersecurity breach of a platform of this kind could create not only a risk to privacy and reputation, but to patient safety as well.
“Diagnostic testing serves a critical role in the care of patients with severe illnesses such as sepsis,” said Dr. Chuck Cooper, vice president, Medical & Scientific Affairs, IDS. “When a breach occurs, patient care may be compromised due to interruptions in laboratory results reporting. Also, concerns about result accuracy and authenticity may create unnecessary confusion that could interfere with optimal patient care. There is little to no room for this kind of disruption in the care of patients with life-threatening conditions.”
The UL CAP incorporates the UL 2900 set of standards, including UL 2900-1, a software cybersecurity standard for network-connected medical devices that has received official recognition from the US Food and Drug Administration.
“We are very pleased to see BD leading the way to help ensure the safety and security of critical laboratory data,” adds Anura Fernando, Chief Innovation Architect, Medical Systems Interoperability & Security at UL. “The importance to clinicians and patients alike of protecting the privacy and security of sensitive health-oriented information cannot be overstated.”
The UL CAP certification for BD Synapsys informatics solution is part of a broad and ongoing BD strategy to partner with government and industry leaders to enhance cybersecurity efforts.
About UL Healthcare
UL LLC Healthcare helps healthcare and medical device companies navigate complex global regulatory systems in order to bring safer, more secure, usable and interoperable products and technologies to patients and healthcare providers. UL Healthcare is a division of Underwriters Laboratories, the company with more than 120 years of product safety expertise. Learn more about UL Healthcare.
About BD Synapsys
BD Synapsys solution enables laboratories to address challenges and improve laboratory outcomes. It enables labs to maximize performance using enhanced microbiology informatics through a single, advanced platform with an intuitive, personalized user interface. BD Synapsys solution offers integrated workflow and on-demand insights to empower laboratory staff to impact turnaround time, expedite decision making, improve productivity and support compliance. Learn more about BD Synapsys.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com